Can This Be Non-Compressive PTB Myelopathy?
Yes, this clinical presentation is highly consistent with non-compressive tuberculous myelopathy (tuberculous myeloradiculitis), and empiric anti-tuberculous therapy should be initiated immediately given the recent pulmonary TB history, progressive ascending weakness, and normal MRI despite clear neurological deficits.
Clinical Reasoning
The constellation of findings strongly supports tuberculous myelopathy:
- Recent pulmonary TB provides the infectious source
- Progressive ascending weakness over 1.5 months matches the subacute-to-chronic timeframe typical of TB myelitis
- Absent plantar responses suggest lower motor neuron involvement (flaccidity/hyporeflexia), which can occur in tuberculous myeloradiculitis affecting nerve roots 1
- Normal non-contrast MRI does NOT exclude tuberculous myelopathy—this is a critical pitfall
The MRI-Negative Myelopathy Phenomenon
A normal MRI does not rule out tuberculous myelopathy. Recent case evidence demonstrates MRI-negative paraplegia secondary to tubercular myeloradiculitis where patients improved with anti-tuberculous therapy despite normal spine imaging 2. The pathophysiology likely involves:
- Early inflammatory changes affecting nerve roots and meninges before parenchymal cord signal changes develop
- Predominant leptomeningeal involvement not visible on non-contrast sequences
- Microscopic vasculitis affecting spinal cord perfusion without gross infarction
You should obtain MRI with contrast immediately 1. Contrast-enhanced spinal cord MRI is specifically recommended for suspected tuberculous myelopathy and can reveal:
- Diffuse leptomeningeal enhancement (70-93% sensitive) 1
- T2-weighted hyperintense lesions that may be subtle
- Enhancement patterns suggesting inflammatory myelitis
Diagnostic Workup Algorithm
Immediate actions:
CSF re-analysis if not already comprehensive:
- Cell count with differential (expect lymphocytic pleocytosis 50-70%) 1
- Protein (typically elevated in TB myelitis)
- Glucose (often decreased)
- ADA levels (adenosine deaminase—highly supportive when elevated) 2, 3
- GeneXpert MTB/RIF Ultra (though sensitivity is suboptimal in CNS TB) 4
- TB culture (gold standard but takes weeks)
- Rule out bacterial/viral meningitis
Blood T-SPOT or IGRA testing 3—positive in recent TB cases and supports diagnosis
Contrast-enhanced MRI spine (if not done) and brain MRI 1, 5—one-third of TB myelitis cases have concurrent CNS manifestations
Chest imaging review—confirm pulmonary TB status and look for active disease 2, 6
Critical Differential Considerations
While pursuing TB diagnosis, rapidly exclude:
Guillain-Barré Syndrome (GBS): Your patient has ascending weakness, but GBS typically shows albumino-cytological dissociation (elevated CSF protein with normal cells). However, 30-50% of GBS patients have normal CSF protein in week 1, and 10-30% in week 2 7. The 1.5-month timeline is longer than typical GBS. Electrodiagnostic studies would show sensorimotor polyradiculoneuropathy in GBS 7
Autoimmune myelitis (NMO, ADEM): Check aquaporin-4 antibodies if longitudinally extensive lesions appear on contrast MRI 1
Compressive lesions: Though MRI is "normal," ensure no subtle epidural collections or vertebral involvement were missed
Treatment Recommendation
Initiate anti-tuberculous therapy immediately without waiting for microbiological confirmation 2, 5, 8, 3, 9. The evidence strongly supports empiric treatment when clinical suspicion is high:
Standard Regimen for CNS TB:
- Duration: 9-12 months minimum (NOT 6 months) 10—CNS TB requires prolonged therapy
- Intensive phase (2 months): Isoniazid + Rifampin + Pyrazinamide + Ethambutol 10
- Continuation phase (7-10 months): Isoniazid + Rifampin 10
Add Corticosteroids:
High-dose glucocorticoids are recommended for tuberculous myelitis 1. The combination of IV methylprednisolone with anti-TB therapy is effective when initiated promptly (within hours to days), with neurological response occurring within days to 3 weeks 1. This is critical—delay beyond 2 weeks is associated with severe neurological deficit 1.
Common Pitfalls to Avoid
Waiting for positive cultures: Mycobacterium tuberculosis is notoriously difficult to isolate from CSF. Multiple cases in the literature were culture-negative but responded to empiric therapy 2, 9
Relying on non-contrast MRI alone: Always obtain contrast sequences for suspected inflammatory/infectious myelopathy 1, 11, 1
Delaying corticosteroids: Start within the first few hours to days—not after waiting for definitive diagnosis 1
Using 6-month regimens: CNS TB requires 9-12 months; shorter courses have inadequate data and higher relapse risk 10
Stopping therapy during corticosteroid taper: Relapses are common (50-60%) during steroid reduction—maintain immunosuppressive therapy throughout 1
Prognosis and Monitoring
Factors predicting poor outcome in TB myelitis 1:
- Extensive spinal cord lesions on MRI
- Reduced muscle strength at presentation
- Sphincter dysfunction
- Delay >2 weeks in initiating therapy
Monitor closely for:
- Clinical improvement within 2-4 weeks
- Repeat MRI at 3 weeks to assess response 1
- Relapse during steroid taper (adjust immunosuppression accordingly)
Given the recent pulmonary TB, normal MRI, progressive myelopathy, and absence of alternative diagnosis, tuberculous myeloradiculitis is the leading diagnosis warranting immediate empiric treatment with anti-tuberculous therapy plus corticosteroids 2, 5, 8, 3, 9.